HB1796 Allowing the use of psilocybin in approved clinical settings to treat qualified medical conditions.
Allowing the use of psilocybin in approved clinical settings to treat qualified medical conditions.
Impact Score — How Does This Bill Affect You?
Overall Impact Score
Mixed
Scale: 1 (harmful) to 10 (beneficial)
Your Wallet
Psilocybin therapy could provide cost-effective treatment for conditions that otherwise require years of expensive conventional therapy.
Your Community
Research shows promising results for psilocybin in treating depression, PTSD, and addiction -- conditions that affect many NH residents.
Your Freedom
Expands medical treatment options and patient autonomy for people suffering from treatment-resistant conditions.
Status
Minority Committee Report: Ought to Pass
Sponsor
Michael Moffett (R)
The Short Version
Would allow clinical use of psilocybin to treat conditions like treatment-resistant depression, PTSD, and addiction under medical supervision. Has minority committee support.
Who's Behind This Bill?
Who Benefits
- ▲ Patients with treatment-resistant depression, PTSD, and addiction
- ▲ Mental health providers
- ▲ Veterans and first responders with PTSD
Who Pays the Price
- ▼ Traditional pharmaceutical interests
- ▼ Regulatory systems managing new treatment modality
Bill statuses as of May 2026. Check LegiScan or NH General Court for the latest.
This bill was auto-scored using AI analysis of the bill text and legislative data. Scores may be refined as we review more bills.